Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PBAX | Class A common stock | Other | +10K | 10K | Oct 8, 2021 | By Phoenix Biotech Sponsor, LLC | F1, F2, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PBAX | Class B Common Stock | Other | +100K | 100K | Oct 8, 2021 | Class A Common Stock | 100K | By Phoenix Biotech Sponsor, LLC | F1, F3, F4 | ||||
transaction | PBAX | Warrants | Other | +5K | 5K | Oct 8, 2021 | Class A Common Stock | 5K | $11.50 | By Phoenix Biotech Sponsor, LLC | F1, F3, F5, F6, F7 |
Id | Content |
---|---|
F1 | Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC. |
F2 | These shares underlie 10,000 units of the issuer purchased by the reporting person. |
F3 | Held directly by the issuer's sponsor, Phoenix Biotech Sponsor, LLC, of which the reporting person is a member. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose. |
F4 | The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. |
F5 | These warrants underlie 10,000 units of the issuer purchased by the reporting person. |
F6 | The warrants will become exercisable at the later of 30 days after the consummation of the issuer's initial business combination or 12 months from the completion of the issuer's initial public offering. |
F7 | The warrants will expire five years after the consummation of the issuer's initial business combination or earlier upon redemption of all of the issuer's outstanding Class A common shares or the issuer's liquidation. |